The Evaluation of Belimumab in Myasthenia Gravis (MG)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

October 31, 2015

Conditions
Myasthaenia Gravis
Interventions
BIOLOGICAL

Belimumab

10mg/kg IV infusion

OTHER

Placebo

placebo IV infusion

Trial Locations (25)

10117

GSK Investigational Site, Berlin

20037

GSK Investigational Site, Washington D.C.

20133

GSK Investigational Site, Milan

22908

GSK Investigational Site, Charlottesville

29425

GSK Investigational Site, Charleston

33136

GSK Investigational Site, Miami

33612

GSK Investigational Site, Tampa

43210

GSK Investigational Site, Columbus

50924

GSK Investigational Site, Cologne

66160

GSK Investigational Site, Kansas City

72076

GSK Investigational Site, Tübingen

77030

GSK Investigational Site, Houston

80907

GSK Investigational Site, Colorado Springs

85018

GSK Investigational Site, Phoenix

90033

GSK Investigational Site, Los Angeles

92868

GSK Investigational Site, Orange

Unknown

GSK Investigational Site, Chapel Hill

17033-0859

GSK Investigational Site, Hershey

05405

GSK Investigational Site, Burlington

T6G 2B7

GSK Investigational Site, Edmonton

V6T 2B5

GSK Investigational Site, Vancouver

N6A 5A5

GSK Investigational Site, London

M5G 2C4

GSK Investigational Site, Toronto

04103

GSK Investigational Site, Leipzig

00185

GSK Investigational Site, Rome

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01480596 - The Evaluation of Belimumab in Myasthenia Gravis (MG) | Biotech Hunter | Biotech Hunter